Sorafenib treatment following hematopoietic stem cell transplant in pediatricFLT3/ITD acute myeloid leukemia

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

(2014) R. F. Schlenk et al.   BLOOD

In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification

(2014) Y. Wang et al.   BLOOD

Cancer Therapy-Induced Left Ventricular Dysfunction: Interventions and Prognosis

(2014) Akanksha Thakur et al.   JOURNAL OF CARDIAC FAILURE

Allogeneic Hematopoietic Cell Transplantation in First Remission Abrogates Poor Outcomes Associated with High-Risk Pediatric Acute Myeloid Leukemia

(2013) Michael J. Burke et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients

(2013) Philip S. Hall et al.   JACC-Heart Failure

Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation

(2012) C. H. Man et al.   BLOOD

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

(2012) S K Metzelder et al.   LEUKEMIA

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

(2012) Edith A. Perez et al.   MAYO CLINIC PROCEEDINGS

Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas

(2012) AeRang Kim et al.   PEDIATRIC BLOOD & CANCER

Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution

(2011) Amy E. DeZern et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib

(2011) Manish Sharma et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia

(2011) Hiroto Inaba et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia

(2011) Emna Abdelhamid et al.   LEUKEMIA RESEARCH

Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia

(2011) Tanya C. Watt et al.   PEDIATRIC BLOOD & CANCER

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Cancer Treatment in Long-Term Overall and Cardiovascular Mortality After Childhood Cancer

(2010) Markhaba Tukenova et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer

(2010) Howard R. Mellor et al.   TOXICOLOGICAL SCIENCES

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

(2009) S. Metzelder et al.   BLOOD

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

(2008) M. Brave et al.   CLINICAL CANCER RESEARCH